FibroBiologics, Inc. Files Amended 10-K/A: Key Details for Investors

Summary of the Filing

On March 13, 2026, FibroBiologics, Inc. (Nasdaq: FBLG), a Houston-based biotechnology firm focused on cell therapy and regenerative medicine, submitted an amended annual report (Form 10-K/A) for the fiscal year ended December 31, 2025. This amendment (Amendment No. 1) addresses the omission of Part III, Items 10-14, from the original 10-K filed on February 24, 2026. These items pertain to corporate governance, executive compensation, beneficial ownership, related party transactions, and accounting fees—information which is vital for shareholders and market participants.

Key Points from the Amended Filing

• Amendment Purpose: The company omitted Part III (Items 10-14) from its original 2025 Annual Report and now provides the requisite details on directors, executive officers, compensation, ownership, and related matters. The amendment also deletes references to proxy statement incorporation and files new executive certifications.
• Corporate Status: FBLG is listed on the Nasdaq Capital Market under the symbol “FBLG”. It is identified as an emerging growth company and a smaller reporting company. As of February 24, 2026, the company had 67,594,722 shares of common stock outstanding, each with a par value of \$0.00001.
• Financial Snapshot: The public float (aggregate market value of shares held by non-affiliates) was approximately \$21.6 million as of June 30, 2025.
• Reporting and Compliance: The company confirms it is not a well-known seasoned issuer, is subject to the reporting requirements of the Exchange Act, and has filed all required reports in the past 12 months.
• Governance and Policies:
  • FBLG’s Code of Ethics and Business Conduct is available on its investor relations website. The company intends to disclose any amendments or waivers to this code for executive officers or directors within four business days.
  • The company has adopted insider trading policies and procedures, which apply to directors, officers, and employees, designed to ensure compliance with securities laws and Nasdaq standards. The policy prohibits trading while in possession of material, nonpublic information and is filed as Exhibit 19.1 to this 10-K/A.
  • No material changes have occurred in the process by which stockholders may nominate board members since the last disclosure.
• Executive Compensation:
  • As a smaller reporting and emerging growth company, FBLG follows scaled SEC disclosure requirements.
  • Named Executive Officers for 2025:
    • Pete O’Heeron, CEO and Chairperson
    • Hamid Khoja, Ph.D., Chief Financial Officer
  • The 2025 Summary Compensation Table (details in the filing) includes salary, non-equity incentive plan compensation, and other compensation. Notably, the company provides healthcare benefits and stock options as part of the executive compensation package.
  • Stock options are valued in accordance with ASC 718; see Note 12 of the 2025 Annual Report for calculation methods.
• Forward-Looking Statements: The amended filing reiterates that it contains forward-looking statements regarding business strategy, clinical trials, regulatory submissions, commercialization, funding, competitive positioning, and market acceptance. The company warns that actual results may differ materially due to risks detailed in the “Risk Factors” section of their filings.
• No Financial Restatements: The amendment does not include or alter any financial statements, nor does it reflect any corrections or restatements of previously reported results. No recovery of incentive compensation is triggered, and the amendment does not update previously reported results.

Potentially Price-Sensitive Information

• Executive and Board Disclosures: Investors should note the detailed disclosures regarding executive compensation, governance, and ownership. Changes in leadership compensation and governance practices can reflect management’s strategic priorities and risk management, and may be scrutinized by institutional investors.
• Market Position and Growth: The company’s status as an emerging growth and smaller reporting company, alongside its market cap and share base, may influence investor perception regarding its scalability, access to capital, and long-term growth prospects.
• Forward-Looking Statements and Risks: The numerous forward-looking statements about product development, regulatory timelines, commercialization, and funding needs underscore ongoing business risks and opportunities that can significantly affect the stock price.
• Insider Trading Policy: The adoption and enforcement of robust insider trading policies are critical for maintaining market integrity and investor confidence, especially for smaller and emerging growth companies.

Investor Takeaways

• This amendment brings FBLG into full compliance with SEC reporting requirements by disclosing previously omitted material corporate governance and executive compensation information.
• Investors should closely review the company’s risk factors, compensation structure, and governance practices as disclosed in this amendment and the original 2025 Annual Report.
• The company’s forward-looking statements and its relatively modest market capitalization suggest that share values may be sensitive to developments in clinical programs, regulatory progress, funding events, or changes in executive leadership.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisor before making investment decisions regarding FibroBiologics, Inc. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

View FibroBiologics, Inc. Historical chart here